Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Ana Maria Montagut, Marc Armengol, Gema Gorjón de Pablo, Roger Estrada-Tejedor, José Ignacio Borrell, Gaël Roué

Producció científica: Article en revista indexadaArticle de revisió (sistemàtica)Avaluat per experts

5 Cites (Scopus)


As a post-translational modification that has pivotal roles in protein degradation, ubiquitination ensures that intracellular proteins act in a precise spatial and temporal manner to regulate diversified cellular processes. Perturbation of the ubiquitin system contributes directly to the onset and progression of a wide variety of diseases, including various subtypes of cancer. This highly regulated system has been for years an active research area for drug discovery that is exemplified by several approved drugs. In this review, we will provide an update of the main breakthrough scientific discoveries that have been leading the clinical development of ubiquitin-targeting therapies in the last decade, with a special focus on E1 and E3 modulators. We will further discuss the unique challenges of identifying new potential therapeutic targets within this ubiquitous and highly complex machinery, based on available crystallographic structures, and explore chemical approaches by which these challenges might be met.

Idioma originalAnglès
Pàgines (de-a)213-229
Nombre de pàgines17
RevistaSeminars in Cell and Developmental Biology
Estat de la publicacióPublicada - de des. 2022


Navegar pels temes de recerca de 'Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer'. Junts formen un fingerprint únic.

Com citar-ho